一年两针”的降脂药物进医保，助力高效降脂疗法从“可用”走向“可及

Core Insights - Novartis has successfully included 2 new products and 4 new indications in the 2025 National Medical Insurance Drug List, including the world's first PCSK9 mRNA interference cholesterol-lowering drug, Leqvio (Inclisiran injection) [1][2] Group 1: Product Approval and Market Impact - Leqvio (Inclisiran injection) received approval from the National Medical Products Administration in August 2023 as an adjunct therapy for adults with primary hypercholesterolemia or mixed dyslipidemia [2] - The drug is indicated for patients who do not reach LDL-C targets despite maximum tolerated doses of statins, and can be used alone or in combination with other lipid-lowering therapies [2] - Since 1987, Novartis has had over 100 innovative drugs and new indications approved in China, with more than 40 drugs included in the National Medical Insurance Drug List since 2017 [2] Group 2: Cardiovascular Disease Context - Cardiovascular diseases are the leading cause of death among urban and rural residents in China, with 2 out of every 5 deaths attributed to these conditions [1] - The number of patients with cardiovascular diseases in China is estimated to be as high as 330 million, with a rising prevalence [1] - LDL-C levels are significantly correlated with the risk of atherosclerotic cardiovascular disease (ASCVD), with higher LDL-C levels indicating a greater risk over a 20-year period [1]